GlaxoSmithKline Pharmaceuticals Limited

NSE GLAXO.NS

GlaxoSmithKline Pharmaceuticals Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD -67.32 M

GlaxoSmithKline Pharmaceuticals Limited Net Cash Used Provided By Financing Activities is USD -67.32 M for the year ending March 31, 2024, a 64.15% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

GlaxoSmithKline Pharmaceuticals Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD -187.78 M, a -171.97% change year over year.
GlaxoSmithKline Pharmaceuticals Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD -69.04 M, a 27.38% change year over year.
GlaxoSmithKline Pharmaceuticals Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD -95.07 M, a -67.54% change year over year.
GlaxoSmithKline Pharmaceuticals Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD -56.75 M, a -10.04% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NSE: GLAXO.NS

GlaxoSmithKline Pharmaceuticals Limited

CEO	Mr. Bhushan Akshikar
IPO Date	July 1, 2002
Location	India
Headquarters	GSK House
Employees	3,211
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Key trends

Past 5 years